COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2025 | 03/31/2025 | 06/30/2024 | 06/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 26.10% | 45.70% | -1.50% | -1.50% | -1.50% |
| Total Depreciation and Amortization | -11.69% | -17.09% | 5.01% | 5.01% | 5.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 218.70% | -95.24% | -473.47% | -473.47% | -443.22% |
| Change in Net Operating Assets | -282.74% | 75.99% | 289.18% | 289.18% | 289.18% |
| Cash from Operations | -136.54% | 37.31% | 41.64% | 41.64% | 42.15% |
| Capital Expenditure | 92.03% | -99.03% | 72.16% | 72.16% | 72.16% |
| Sale of Property, Plant, and Equipment | -75.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 42.86% | -- | -- | -- |
| Cash from Investing | 92.20% | -94.62% | 4,688.65% | 4,688.65% | 4,688.65% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 67.50% | -83.49% | -34.04% | -34.04% | -75.00% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 46.50% | 0.99% | -34.04% | -34.04% | -75.00% |
| Foreign Exchange rate Adjustments | 195.00% | 168.18% | 50.00% | 50.00% | 50.37% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -67.93% | 26.91% | 866.02% | 866.02% | 866.02% |